-7.4%
RKLB vs MRNA
+945.0%
-952.4%
-66.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.8% | +13.1% | -16.9% | -4.5% |
| 7D | -10.6% | +20.6% | -31.3% | -11.6% |
| 30D | -28.3% | +27.1% | -55.4% | -29.3% |
| 3M | -29.7% | +353.4% | -383.1% | -40.9% |
| 6M | -34.8% | +446.3% | -481.0% | -51.7% |
| YTD | -24.9% | +776.2% | -801.1% | -59.1% |
| 1Y | -7.4% | +987.9% | -995.3% | -54.8% |
| All | -7.4% | +945.0% | -952.4% | -54.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling